Ambizas Emily M, Ginzburg Regina
College of Pharmacy & Allied Health Professions, St John's University, Queens, NY 11439, USA.
Ann Pharmacother. 2007 Jun;41(6):957-64. doi: 10.1345/aph.1K047. Epub 2007 May 22.
To review lubiprostone's pharmacology, pharmacokinetics, efficacy, and safety in the treatment of chronic constipation.
A literature search was conducted using PubMed/MEDLINE (1966-January 2007), IngentaConnect, and International Pharmaceutical Abstracts (1977-January 2007). Key words used included lubiprostone, Amitiza, and chronic constipation.
All articles identified from the data sources that were published in English were evaluated.
Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours. Phase III trials have noted that most patients with chronic constipation have a spontaneous bowel movement within 24 hours after taking lubiprostone. The most common adverse events in these trials were nausea, diarrhea, abdominal pain, and headache. Lubiprostone use has not been studied in the pediatric population.
Lubiprostone may be a reasonable alternative for use in patients who either fail or are intolerant of standard therapy for chronic constipation. Head-to-head comparison studies with conventional therapy are needed to contrast clinical efficacy and safety of this medication.
综述鲁比前列酮在治疗慢性便秘方面的药理学、药代动力学、疗效及安全性。
使用PubMed/MEDLINE（1966年至2007年1月）、IngentaConnect以及国际药学文摘（1977年至2007年1月）进行文献检索。使用的关键词包括鲁比前列酮、Amitiza和慢性便秘。
对从数据源中识别出的所有英文发表文章进行评估。
鲁比前列酮是一种经美国食品药品监督管理局批准用于治疗慢性便秘的氯通道激活剂。一项评估鲁比前列酮对胃功能影响的随机、双盲、平行组、安慰剂对照研究显示胃排空减慢，小肠和结肠转运时间增加。血浆峰浓度显示在1.14小时左右，大部分药物在48小时内随尿液排出。III期试验指出，大多数慢性便秘患者在服用鲁比前列酮后24小时内会自发排便。这些试验中最常见的不良事件是恶心、腹泻、腹痛和头痛。尚未在儿科人群中研究鲁比前列酮的使用情况。
对于慢性便秘标准治疗无效或不耐受的患者，鲁比前列酮可能是一种合理的替代药物。需要与传统疗法进行直接对比研究，以比较该药物的临床疗效和安全性。
